We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Coagulation Parameters During Pregnancy in Amniotic Fluid

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2007 by Rambam Health Care Campus.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00458666
First Posted: April 11, 2007
Last Update Posted: April 11, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Rambam Health Care Campus
  Purpose
Amniotic fluid embolism is a rare devastating thromboembolic event, which is probably caused by the entrance of amniotic fluid (AF) to the maternal circulation. While AF contains coagulation activators, their role during pregnancy has not been elucidated. The current study aimed to evaluate coagulation parameters in AF during human pregnancy.

Condition
Pregnancy

Study Type: Observational
Study Design: Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Coagulation Parameters During Pregnancy in Amniotic Fluid

Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment: 170
Study Start Date: June 2006
Detailed Description:
Amniotic fluid embolism is a rare devastating thromboembolic event, which is probably caused by the entrance of amniotic fluid (AF) to the maternal circulation. While AF contains coagulation activators, their role during pregnancy has not been elucidated. The current study aimed to evaluate coagulation parameters in AF during human pregnancy.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Women undergoing amniocentesis during 15-35 weeks of gestation.

Exclusion Criteria:

  • A history of venous thromboembolism
  • Systemic disease i.e.; diabetes, hypertension, hypo or hyper-thyroidism,
  • Anticoagulant treatment
  • Abnormal embryo
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00458666


Contacts
Contact: Galit Sarig, Ph.D +972-50-2061462 g_sarig@rambam.health.gov.il

Locations
Israel
Dept of Obstetrics and Gynecology, Rambam-Health Care Campus Recruiting
Haifa, Israel
Contact: Arie Drugan, M.D    +972-50-206-2006    a_drugan@rambam.health.gov.il   
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Benjamin Brenner, M.D Rambam Health Care Campus
Study Chair: Arie Drugan, M.D Rambam Health Care Campus
  More Information

ClinicalTrials.gov Identifier: NCT00458666     History of Changes
Other Study ID Numbers: CoagulationAmnioticFluid_CTIL
First Submitted: April 10, 2007
First Posted: April 11, 2007
Last Update Posted: April 11, 2007
Last Verified: March 2007

Keywords provided by Rambam Health Care Campus:
Amniotic fluid
D-dimer
coagulation
factor X activation